AstraZeneca is stopping a lung cancer treatment trial, according to multiple reports. The company halts a stage trial testing a drug referred to by outlets as volrustomig, with the decision coming about a month after it stopped a separate trial for a new heart disease treatment.
The articles frame the move as another setback for the drugmaker. While the coverage focuses on the timing—ending the lung cancer study shortly after the earlier pause—outlets vary mainly in emphasis. The Evening Standard and The Independent highlight the sequence of trial stoppages, presenting it as part of a broader pattern of clinical trial discontinuations. The Independent also describes the decision in the context of the company’s ongoing challenges, though specific reasons for either stop are not detailed in the provided excerpts.
Overall, the reports agree on what AstraZeneca does—ending the lung cancer trial—and when it does it—roughly one month after halting a heart disease trial—without citing new trial data or offering additional justification in the summaries.